What is Complexa?
Complexa Inc. operates at the intersection of biotechnology and clinical development, focusing on the discovery and advancement of novel therapies for life-threatening inflammatory diseases. By targeting the underlying mechanisms of fibrosis, the company has positioned itself as a critical player in the biopharma sector. Its market position is bolstered by a history of sustained financial support, allowing for the rigorous testing and development cycles required in the pharmaceutical industry. The company's commitment to transforming patient outcomes through scientific rigor remains the cornerstone of its operational strategy.
How much funding has Complexa raised?
Complexa has raised a total of $90.1M across 10 funding rounds:
Private Equity
$2M
Series A
$3.6M
Debt
$1.4M
Private Equity
$200K
Series B
$14.8M
Debt
$4M
Debt
$950K
Debt
$1M
Series C
$62M
Debt
$150K
Private Equity (2012): $2M, investors not publicly disclosed
Series A (2012): $3.6M led by Pittsburgh Life Sciences Greenhouse
Debt (2013): $1.4M, investors not publicly disclosed
Private Equity (2013): $200K featuring Pittsburgh Life Sciences Greenhouse
Series B (2014): $14.8M backed by Pittsburgh Life Sciences Greenhouse
Debt (2015): $4M, investors not publicly disclosed
Debt (2016): $950K, investors not publicly disclosed
Debt (2016): $1M, investors not publicly disclosed
Series C (2017): $62M featuring JAFCO, Edmond de Rothschild Investment Partners, New Enterprise Associates, and HBM Healthcare Investments
Debt (2020): $150K backed by PPP
Key Investors in Complexa
JAFCO
JAFCO Group Co., Ltd. specializes in venture investments aimed at startups that challenge the creation of new businesses, as well as buyout investments targeting small to medium-sized enterprises seeking to achieve re-growth.
Edmond de Rothschild Investment Partners
Edmond de Rothschild, founded in 1923 and headquartered in France, is an investment banking firm offering various financial services and solutions.
New Enterprise Associates
Established in 1977 and headquartered in Menlo Park, California, New Enterprise Associates is a venture capital firm focused on helping entrepreneurs build businesses.
What's next for Complexa?
With the recent infusion of capital, Complexa is well-positioned to accelerate its clinical trial milestones and expand its research capabilities. The company's trajectory suggests a focus on scaling its development infrastructure to meet the growing demand for effective treatments in the fibrosis space. As it moves through its current lifecycle stage, the firm will likely prioritize strategic partnerships and regulatory milestones to ensure the successful commercialization of its therapeutic candidates. Investors remain focused on the company's ability to translate its scientific breakthroughs into tangible clinical results, which will be pivotal for its long-term growth and market valuation.
See full Complexa company page
